State-owned contraceptives manufacturer HLL Lifecare Ltd said it plans to come up with an initial public offer (IPO) to raise funds in next nine months.
Earlier known as Hindustan Latex, the company plans to invest Rs570 crore in new projects such as setting up a 'Vaccine Complex' and 'Medipark'. The vaccine complex is being set up at Chingleput in Tamil Nadu. Besides the vaccine complex, the company is also setting up a 'Medipark' to manufacture medical equipment.
Established in 1966, the company started operations in 1969 under the Ministry of Health and Family Welfare. It manufactures a host of health-care products, including condoms, contraceptive pills, Copper T and medical devices
DQ Entertainment (International) Ltd has signed an exclusive publishing licensing deal for 'The Jungle Book', through DQE's merchandising agents in Germany-ZDF Enterprises, with Egmont Verlagsgesellschaften GmbH. The company has also inked a non-exclusive deal with Belltex, Belgium for retailing Jungle Book based products in Germany, Australia and Switzerland.
According to the agreement, Egmont has the right to manufacture and distribute German language books in a variety of formats such as character books, friendship books etc. Egmont has been granted publishing rights for The Jungle Book in German speaking Europe. DQE will receive a royalty on sales through this deal from Egmont, in addition to a substantial upfront payment as a minimum guaranteed amount.
Under the non-exclusive agreement, Belltex SA, has been authorised to manufacture and distribute bed linen and other similar products based on the The Jungle Book character license. Belltex has been provided the rights for retailing the products in Germany, Austria and Switzerland.
On Tuesday, DQ Entertainment declined 0.69% to Rs93.70 on the Bombay Stock Exchange, while the benchmark Sensex closed 0.60% at 19,521.25 points.
Venus Remedies Ltd (VRL), a research based pharmaceutical company, has received patent for its product Vancoplus from Republic of South Africa and New Zealand.
Vancoplus is used to combat Methilicillin Resistant Staphylococcus Aureus (MRSA). Dr Manu Chaudhary, JMD, Venus Remedies says, "Vancoplus is a brand of Ceftriaxone and Vancomycin along with chemical vector used in CVMC technology which has a potential to restrict production of toxin produced by MRSA. Vancoplus therapy reduces treatment time and cost and is a boon for medical field." The patent for Vancoplus is valid till February 2026 in both the countries.
Vancoplus has been successfully launched in few markets globally and has achieved sales of $3.5 million in three years. The product is under registration in many countries. The patent of this product has also been filed in US, Canada, Europe, Ukraine, Russia etc besides India and the grant is expected to be received soon.
The pharmaceutical market size of South Africa was worth $3.03 billion in 2007 and that it should reach $4.41 billion by 2012 and the current size of the New Zealand pharmaceutical market is $379 million.
On Tuesday, Venus Remedies ended 1.11% down at Rs254.10 on the Bombay Stock Exchange, while the benchmark Sensex closed 0.60% at 19,521.25 points.